- Nektar continues to appreciate shareholders as the market and analysts are viewing the firm favorably.
- NDA for NKTR-181 will be filed in April 2018 (and approval is most likely to come in less than a year).
- This is the abridged version of followed-up report to the exclusive Integrated BioSci Research (the deep-dive analysis into Nektar) that we published far in advance for IBI subscribers.
On Dec. 7, 2017, the shares of Nektar Therapeutics (NASDAQ:NKTR) – a bioscience firm focusing on the innovation and delivery of drugs to treat cancers, autoimmune diseases, and chronic pain – increased by $5.14 to close at $54.83 for 10.34% profits for the trading session. The company currently has the $8.63B market cap that was approximately doubled within the past month. Since we initially recommended this stellar grower, subscribers of Integrated BioSci Investing have enjoyed over 187% profits. As alluded, the market is becoming more optimistic about Nektar.
Among eight analysts covering Nektar, seven issued the buy recommendation while only one put a hold on the stock, as shown in figure 2. The recent market enthusiasm stemmed from the stellar earnings developments and especially pipeline growth. Let us explore further why the stock appreciated robustly (and whether there is more upcoming growth ahead).